1800 244 735

Helpline (02) 9874 9777

Shooting the messenger with single-stranded RNA gene silencing

After huge leaps forward in recent years, we’re edging ever closer to human trials of huntingtin lowering or ‘gene silencing’ as a potential treatment for Huntington’s Disease. Newer, better and safer techniques are always welcome and the announcement of ‘single-stranded RNA’ silencing is causing quite a hubbub. What’s it all about?

Gene silencing drugs work by telling cells not to make the huntingtin protein, the cause of damage in Huntington’s disease. They do this by interfering with the cells' protein-making systems.

There are two main types of gene silencing drug: anti-sense oligonucleotides (ASOs) and RNA interference (RNAi). This article is about RNA interference.

While pushing towards clinical trials as rapidly as possible, scientists have also been working on developing a new, and hopefully improved, RNA interference technique. To explain the differences from existing techniques we need to explain a bit about how genes are read to make proteins. Stick with us – it’ll be worth it!

What are DNA and RNA?

DNA is the blueprint for making humans. It is a long molecule made up of stuck-together bits called bases which come in 4 ‘flavours’ – C A G and T. These are the letters in which our genetic code is written.

The DNA ‘double helix’ is made up of two strands that line up side by side. Each strand is a string of bases, and the two strands are held together by chemical bonds between the bases on opposite strands. A pairs with T, and C pairs with G.

To get from DNA to a protein, a ‘working copy’ of the DNA needs to be made. The copy is called ‘messenger’ RNA, or mRNA. RNA is closely related to DNA but looks a little different.

mRNA is the template which tells a cell how to put a protein together. Whenever a cell makes any protein – including the huntingtin protein – it does so by reading the instructions in the mRNA that corresponds to that protein.

Interfering with huntingtin mRNA – or ‘shooting the messenger’ – prevents the huntingtin protein from being put together, and is the basis of gene silencing in RNA interference.

OK – back to gene silencing

So far, RNA-based gene silencing techniques have used double-stranded RNA molecules, called siRNA. Double-stranded RNA was needed until now, because single-stranded RNA is destroyed by the cells' own garbage-clearing mechanisms before it can do any silencing.

Once inside cells, the double-stranded RNA needs to separate into single strands to let it bind to the huntingtin mRNA message molecule. Then an enzyme in cells chews up the mRNA, so that the mutant protein never gets made.

We know that this way of doing things can dramatically decrease the amount of the mutant HD protein made in cells. What we are less sure about is whether the unwanted strand that separates off has any bad side effects on cells. There is a possibility that the body might launch an attack on the leftover strand and cause harm. Another possibility is that the leftover strand might bind to other mRNA, and prevent other important proteins from being made.

Double-stranded siRNA molecules don’t spread very far within the brain, making treating large brain areas difficult.

A final difficulty of double-stranded siRNAs is that they need to be packaged up in a complicated way in order to get them to the right tissues for them to do their job.

There have been studies in mice and monkey animal models of Huntington’s disease which showed that siRNAs are safe and effective, but scientists are a cautious bunch because we have to be really sure about safety before giving any treatments to precious humans. The last thing we want to do is make HD worse.

Single-stranded siRNA

One idea for reducing the risk of bad effects of RNA interference is to produce a single-stranded siRNA. But how could we overcome the stability problem – that annoying habit of cells of chopping up the single-stranded RNA drug?

After a lot of hard work, a group of researchers headed by David Corey in Dallas, in collaboration with ISIS pharmaceuticals have just announced they’ve finally cracked it. To give you an idea of the excitement this has caused, it was announced in not one, but two ‘back-to-back’ articles in the same edition of top journal Cell. Quite a scoop!

By making some chemical modifications to previous attempts, Corey’s team have made a single-stranded siRNA, and were able to package it in a simple salt water solution. They successfully injected the single-stranded siRNA into the fluid spaces which surround the brain in a mouse model of HD, and were able to show that it binds to huntingtin mRNA and prevents the HD protein from being made.


What’s more, unlike double-stranded siRNA drugs that have been tested before, the effects of single-stranded siRNA spread throughout the brain rather than being confined to the small area near the injection. In these mice at least, single-stranded siRNA produced a win-win: it was stable and it spread further.

Not content with that, they took things further. By slightly altering the structure of their molecule, they could also create a single-stranded siRNA which only blocked production of the mutant HD protein and didn’t prevent the normal version of the HD protein from being made. They did this by targeting the siRNA to the abnormally long ‘CAG’ stretch in the HD gene.

With a single-stranded siRNA we don’t need to worry about what a second strand might be doing, and by targeting just the mutant huntingtin mRNA there’s less concern about the possible effects of stopping production of the normal HD protein.

What next?

So this new method looks safe and effective in mouse models. Now we need to make sure it is safe and effective in other, larger animal models before even considering going into human trials. That’s happening now!

Remaining questions

A few questions will need to be answered before single-stranded RNA interference can be tested in people.

First, there are some other genes with a stretch of CAGs in them. We don’t yet know if introducing single-stranded siRNAs targeting those CAG stretches might inadvertently switch off other important genes.

Second, the delivery problem. How are we going to reach the important parts of the brain of Huntington’s disease patients? Luckily, researchers in HD and other diseases are already working on this. A trial of a similar drug made from single-stranded DNA is being trialled in motor neuron disease (ALS) right now.

Finally, how are we going to measure and monitor the effectiveness of treatment? In animal models, we can do this by looking at brain tissue and measure how much huntingtin protein is made. This is a lot more tricky to do in humans, but top scientists are working on it and we think we’re ready to start trials in Huntington’s disease patients.

More potential uses for single-stranded siRNA

A final sneak preview of another possible use of single-stranded siRNA. Researchers are also looking at using it in combination with stem cell research. Basically, they are working on taking skin cells from individuals with Huntington’s disease, and turning those skin cells into neurons. Those neurons could then be treated with single-stranded siRNAs to reduce the levels of harmful HD protein before transplanting them back into the brain.

It’ll be many years before the combination of single-stranded siRNA with patient-derived stem cells might be used as a treatment, but it’s a neat idea and good to know all avenues are being explored. Meanwhile we expect single-stranded siRNA to progress fairly rapidly towards clinical trials.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Plenary Meeting 2020

Published date: 8 January, 2021

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more

Uncovering the dark side of DNA repair to design HD treatments

Published date: 22 December, 2020

A gene known as ‘MSH3’, which encodes a protein involved in fixing and maintaining our DNA, has become a hot topic in Huntington’s research since being implicated as a key driver of the disease by multiple genetic studies. In a recent publication, a team of scientists from the National University of Ireland, Galway, have provided ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 2

Published date: 1 November, 2020

The second day of the HSG conference was another busy day of presentations from HD researchers and clinicians. The day kicked off with a talk from Vaccinex who gave us an overview of their work on the SIGNAL clinical trial. Unfortunately, pepinemab, the medicine tested in this trial, did not influence HD symptoms and the ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 1

Published date: 30 October, 2020

The Huntington Study Group (HSG) is a clinical research network focused exclusively on HD. Yesterday the HSG annual conference began with a schedule jam-packed with virtual talks from researchers, clinicians and different companies who are all working towards finding new medicines for HD. The day encompassed many interesting presentations which covered a lot of the ... Read more

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Published date: 22 October, 2020

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam. An existing drug…for huntingtin lowering? The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration ... Read more

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more